Carotuximab
drug drugOn this page
Also known as DE-122TRC-105Trc105c-SN6j
Summary
Carotuximab (CHEMBL2109321) is a phase-3 clinical-stage antibody targeting ENG; indicated across 23 conditions including angiosarcoma and glioblastoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (ENG)
- Indications: 23 conditions
- Clinical trials: 23
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109321 |
| Name | Carotuximab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Carotuximab, DE-122, TRC-105, Trc105, c-SN6j, CAROTUXIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ENG | endoglin (CD105) | Binding | 9 | 0.2% | P17813 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): ENG.
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of transcription by RNA polymerase II | 1 |
| branching involved in blood vessel morphogenesis | 1 |
| vasculogenesis | 1 |
| response to hypoxia | 1 |
| negative regulation of endothelial cell proliferation | 1 |
| heart looping | 1 |
| positive regulation of systemic arterial blood pressure | 1 |
| outflow tract septum morphogenesis | 1 |
| epithelial to mesenchymal transition involved in endocardial cushion formation | 1 |
| endocardial cushion morphogenesis | 1 |
| cardiac ventricle morphogenesis | 1 |
| cardiac atrium morphogenesis | 1 |
| ventricular trabecula myocardium morphogenesis | 1 |
| cell migration involved in endocardial cushion formation | 1 |
| regulation of DNA-templated transcription | 1 |
Indications & clinical
Indications
18 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| angiosarcoma | 3 | MONDO:0016982 | EFO:0003968 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| clear cell renal carcinoma | 2 | MONDO:0005005 | EFO:0000349 |
| papillary renal cell carcinoma | 2 | MONDO:0017884 | EFO:0000640 |
| renal cell carcinoma | 2 | MONDO:0005086 | EFO:0000681 |
| choriocarcinoma | 2 | MONDO:0005207 | EFO:0002893 |
| age-related macular degeneration | 2 | MONDO:0005150 | EFO:0001365 |
| placental site trophoblastic tumor | 2 | MONDO:0020552 | EFO:1001111 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| anaplastic astrocytoma | 1 | MONDO:0016684 | EFO:0002499 |
| anaplastic oligodendroglioma | 1 | MONDO:0016696 | EFO:0002501 |
| non-small cell lung carcinoma | 1 | MONDO:0005233 | EFO:0003060 |
| gliosarcoma | 1 | MONDO:0016681 | EFO:1001465 |
| soft tissue sarcoma | 1 | MONDO:0018078 | EFO:1001968 |
| glioma | 1 | MONDO:0021042 | MONDO:0003268 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
| lung neoplasm | 1 | MONDO:0021117 | MONDO:0008903 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 23.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| PHASE1/PHASE2 | 7 |
| PHASE1 | 5 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02979899 | PHASE3 | COMPLETED | Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma |
| NCT05534646 | PHASE2 | RECRUITING | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer |
| NCT01090765 | PHASE1/PHASE2 | COMPLETED | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) |
| NCT01326481 | PHASE1/PHASE2 | COMPLETED | Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer |
| NCT01328574 | PHASE2 | COMPLETED | TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma |
| NCT01375569 | PHASE2 | COMPLETED | TRC105 for Liver Cancer That Has Not Responded to Sorafenib |
| NCT01381861 | PHASE2 | COMPLETED | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
| NCT01564914 | PHASE2 | COMPLETED | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma |
| NCT01778530 | PHASE2 | TERMINATED | TRC105 for Recurrent Glioblastoma |
| NCT01806064 | PHASE1/PHASE2 | TERMINATED | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma |
| NCT01975519 | PHASE1/PHASE2 | COMPLETED | A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma |
| NCT02396511 | PHASE2 | COMPLETED | TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma |
| NCT02520063 | PHASE1/PHASE2 | COMPLETED | Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer |
| NCT02555306 | PHASE1/PHASE2 | COMPLETED | A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration |
| NCT02560779 | PHASE1/PHASE2 | COMPLETED | Trial of TRC105 and Sorafenib in Patients With HCC |
| NCT02664961 | PHASE2 | TERMINATED | Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) |
| NCT03418324 | PHASE2 | COMPLETED | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy |
| NCT05401110 | PHASE1 | RECRUITING | Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer |
| NCT01332721 | PHASE1 | COMPLETED | Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated |
| NCT02429843 | PHASE1 | COMPLETED | A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer |
| NCT03181308 | PHASE1 | COMPLETED | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC |
| NCT03780010 | PHASE1 | COMPLETED | Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC |
| NCT02354612 | Not specified | NO_LONGER_AVAILABLE | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: ENG
- In clinical trials for: angiosarcoma, glioblastoma, hepatocellular carcinoma, clear cell renal carcinoma, papillary renal cell carcinoma, renal cell carcinoma, choriocarcinoma, age-related macular degeneration